U.S. markets closed

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.88-1.00 (-3.59%)
At close: 04:00PM EDT
26.00 -0.88 (-3.27%)
After hours: 06:38PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close27.88
Bid26.00 x 1200
Ask28.20 x 800
Day's Range26.57 - 28.11
52 Week Range26.57 - 52.40
Avg. Volume820,523
Market Cap2.58B
Beta (5Y Monthly)0.74
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CYTK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cytokinetics, Incorporated
    CYTK: Rating increased to a HOLDCYTOKINETICS INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • GlobeNewswire

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 29, 2023 it granted stock options to purchase an aggregate of 5,700 shares of common stock to two new employees, whose employment commenced in September 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $29.46 per share, which is equal to the closing price of the Company’s common stock

  • GlobeNewswire

    Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

    Baseline Characteristics from SEQUOIA-HCM to be Presented at HCMS Scientific Sessions on October 6, 2023SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced upcoming presentations at the 2023 Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on October 6, 2023, and at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place from October 6-9, 2023, both taking place in Cleveland, O

  • GlobeNewswire

    Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program

    Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 1st, 2023 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the sixth annual Cytokinetics Communications Grant Program. The program will award five grants in the amount of $20,000 each to patient advocacy or